1. [CASE 1 — QUESTION 1]
A 45-year-old man returns from a 3-week trip to rural Ghana, where he took no malaria prophylaxis. He presents with 4 days of high fever and is now drowsy and difficult to rouse. Temperature is 39.8 C, he is tachycardic and hypotensive, and he has scleral icterus. A thick and thin blood smear shows Plasmodium falciparum at 9 percent parasitemia. Laboratory studies show a lactate of 5.5 mmol/L, creatinine 2.1 mg/dL, and a blood glucose of 58 mg/dL. He is admitted to the intensive care unit. What is the most appropriate immediate antimalarial treatment?
A) Oral artemether-lumefantrine once he is able to swallow
B) Oral chloroquine by nasogastric tube
C) Intravenous artesunate, because he meets criteria for severe malaria (impaired consciousness, hyperparasitemia, acidosis, and acute kidney injury)
D) Intramuscular primaquine for radical cure
E) Oral atovaquone-proguanil at treatment dose
ANSWER: C
Rationale:
This patient meets several criteria for severe Plasmodium falciparum malaria: impaired consciousness, hyperparasitemia above 5 percent, metabolic acidosis with elevated lactate, acute kidney injury, and hypoglycemia. Severe malaria mandates immediate parenteral therapy, and intravenous artesunate is first-line, reducing mortality compared with intravenous quinine; glucose and supportive care are addressed concurrently. This is correct.
Option A: Option A is incorrect because a drowsy patient with severe disease should not receive oral therapy, which may be poorly absorbed and is too slow for life-threatening illness.
Option B: Option B is incorrect because chloroquine is inappropriate for severe falciparum (resistance and inadequate efficacy) and nasogastric dosing is unsafe in an obtunded patient.
Option D: Option D is incorrect because primaquine is an 8-aminoquinoline for radical cure and transmission blocking, not a treatment for acute severe malaria.
Option E: Option E is incorrect because oral atovaquone-proguanil is inappropriate for a critically ill patient requiring parenteral therapy.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. He receives intravenous artesunate and improves rapidly, with parasite clearance and resolution of his acidosis and mental status over 3 days. He is counseled about follow-up after discharge. Which delayed complication of artesunate therapy specifically warrants monitoring of his hemoglobin in the weeks after treatment?
A) Post-artesunate delayed hemolysis, a recognized fall in hemoglobin occurring roughly 1 to 3 weeks after treatment, particularly after high initial parasitemia, due to delayed clearance of once-infected (pitted) erythrocytes
B) Cinchonism with progressive sensorineural hearing loss
C) Irreversible retinopathy from cumulative drug deposition
D) Disulfiram-like reaction on alcohol exposure
E) Drug-induced long QT syndrome developing weeks after the infusion
ANSWER: A
Rationale:
Post-artesunate delayed hemolysis is a well-described phenomenon in which hemoglobin falls roughly 1 to 3 weeks after artesunate treatment, especially following high initial parasitemia. It is attributed to the delayed clearance of formerly infected erythrocytes that were "pitted" of their parasites by the spleen and returned to the circulation with a shortened lifespan; patients should have hemoglobin monitored for several weeks after treatment. This is correct.
Option B: Option B is incorrect because cinchonism with hearing loss is a toxicity of quinine and quinidine, not artesunate.
Option C: Option C is incorrect because cumulative retinopathy is a toxicity of chloroquine and hydroxychloroquine, not artesunate.
Option D: Option D is incorrect because a disulfiram-like reaction is not a recognized artesunate effect (it is associated with certain antiprotozoals such as metronidazole and tinidazole).
Option E: Option E is incorrect because delayed-onset long QT syndrome is not the characteristic post-artesunate complication; the monitored concern is delayed hemolysis.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. After 24 hours of intravenous artesunate he is alert, hemodynamically stable, and tolerating oral intake. The team plans to transition him off intravenous therapy. What is the most appropriate next step in his antimalarial management?
A) Stop all antimalarial therapy now that he has clinically improved and his parasitemia has fallen
B) Continue intravenous artesunate indefinitely as monotherapy until the next outpatient visit
C) Transition to oral chloroquine to complete treatment
D) Complete treatment with a full course of an oral artemisinin-based combination therapy (for example artemether-lumefantrine) once he can take oral medication, following the parenteral artesunate
E) Switch to oral primaquine to finish the course
ANSWER: D
Rationale:
After at least 24 hours of parenteral artesunate and once the patient can tolerate oral intake, treatment is completed with a full course of an effective oral artemisinin-based combination therapy (such as artemether-lumefantrine). This follow-on course ensures complete parasite clearance and prevents recrudescence. This is correct.
Option A: Option A is incorrect because stopping after clinical improvement and partial parasite reduction risks recrudescence; a full follow-on course is required.
Option B: Option B is incorrect because indefinite artesunate monotherapy is not the regimen; oral combination follow-on is standard once the patient can swallow.
Option C: Option C is incorrect because chloroquine is inappropriate given chloroquine-resistant falciparum from West Africa.
Option E: Option E is incorrect because primaquine does not provide blood-stage treatment for falciparum and is not the follow-on therapy; falciparum forms no hypnozoites requiring radical cure.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. In a malaria-elimination program context, the team considers adding a single low dose of primaquine to his falciparum treatment. What is the specific purpose of a single low-dose of primaquine in this setting?
A) To eradicate dormant liver hypnozoites and prevent relapse of falciparum malaria
B) To act as a gametocytocidal, transmission-blocking measure by clearing mature Plasmodium falciparum gametocytes from the blood, reducing onward transmission to mosquitoes
C) To provide the primary blood-stage cure in place of the artemisinin combination
D) To reverse artemisinin resistance in the treating regimen
E) To prevent post-artesunate delayed hemolysis
ANSWER: B
Rationale:
A single low dose of primaquine is added to falciparum treatment as a gametocytocidal, transmission-blocking measure: it clears the mature sexual-stage gametocytes from the patient's blood so a feeding mosquito does not acquire viable parasites, supporting elimination efforts. The single low dose is recommended without the need for G6PD testing because the hemolytic risk at that dose is low. This is correct.
Option A: Option A is incorrect because falciparum does not form hypnozoites, so there is no relapse reservoir to eradicate; antirelapse therapy applies to vivax and ovale.
Option C: Option C is incorrect because primaquine does not provide the primary blood-stage cure; the artemisinin combination does.
Option D: Option D is incorrect because primaquine does not reverse artemisinin resistance.
Option E: Option E is incorrect because single low-dose primaquine is not a treatment for post-artesunate delayed hemolysis; that complication is managed by monitoring and transfusion if needed.
5. [CASE 2 — QUESTION 1]
A 26-year-old woman is diagnosed with Plasmodium vivax malaria after returning from India and is treated with chloroquine, with prompt resolution of her acute symptoms. She does not travel again. Ten weeks later she develops recurrent fevers, and a smear again confirms P. vivax. With no possibility of re-exposure, what is the most likely explanation for this recurrence?
A) Chloroquine resistance in the original infecting strain
B) A new infection acquired from a local mosquito in her home country
C) Recrudescence of a chloroquine-resistant blood-stage population that survived treatment
D) Laboratory error in the original diagnosis
E) Relapse from dormant liver hypnozoites of P. vivax that chloroquine did not eradicate, because she received no 8-aminoquinoline for radical cure
ANSWER: E
Rationale:
Plasmodium vivax forms dormant liver hypnozoites that blood-stage drugs such as chloroquine cannot eradicate. Without a terminal 8-aminoquinoline (primaquine or tafenoquine) for radical cure, these hypnozoites reactivate weeks to months later, producing relapse. With no re-exposure, recurrence at 10 weeks is relapse from hypnozoites. This is correct.
Option A: Option A is incorrect because the acute illness responded promptly to chloroquine, and the delayed recurrence pattern after no re-exposure indicates hypnozoite relapse rather than blood-stage resistance.
Option B: Option B is incorrect because she did not travel again and reinfection by a local vector is not the expected explanation in a non-endemic home setting.
Option C: Option C is incorrect because recrudescence is early regrowth of surviving blood-stage parasites, typically within weeks of treatment, not a relapse at 10 weeks from the liver; the hallmark of vivax recurrence after blood-only treatment is hypnozoite relapse.
Option D: Option D is incorrect because the recurrence is confirmed P. vivax on smear, consistent with relapse, not a prior laboratory error.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. The team plans to treat the relapse and this time prevent further relapses by adding radical-cure therapy. Before prescribing primaquine, which step is specifically required?
A) Obtain a quantitative glucose-6-phosphate dehydrogenase (G6PD) level, because primaquine causes dose-dependent oxidative hemolysis in G6PD-deficient patients
B) Obtain a baseline electrocardiogram, because primaquine characteristically prolongs the QT interval
C) Obtain a baseline retinal examination, because primaquine deposits in the retina
D) Obtain baseline audiometry, because primaquine causes cinchonism
E) No testing is required before primaquine
ANSWER: A
Rationale:
Primaquine is an 8-aminoquinoline that generates oxidative metabolites and causes dose-dependent hemolytic anemia in G6PD-deficient patients. A quantitative G6PD level is therefore mandatory before prescribing primaquine for radical cure. This is correct.
Option B: Option B is incorrect because clinically important QT prolongation is associated with quinine, quinidine, and certain ACT partner drugs, not primaquine, and an electrocardiogram is not the required pre-primaquine screen.
Option C: Option C is incorrect because retinal deposition is a concern of long-term chloroquine and hydroxychloroquine, not primaquine.
Option D: Option D is incorrect because cinchonism is a quinine and quinidine toxicity, not a primaquine effect requiring audiometry.
Option E: Option E is incorrect because G6PD testing is specifically required before primaquine to prevent potentially severe hemolysis.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. Her quantitative G6PD activity returns normal. The acute relapse is again treated with an appropriate blood schizonticide. What is the most appropriate radical-cure regimen to prevent further relapses?
A) No additional therapy, because a normal G6PD level means relapse cannot recur
B) Indefinite weekly chloroquine suppression in place of radical cure
C) A standard course of primaquine (for example a daily 14-day regimen, or an equivalent approved radical-cure dosing), now that G6PD deficiency has been excluded, to eradicate the dormant liver hypnozoites
D) A single low dose of primaquine, the dose used only for falciparum transmission blocking
E) Doxycycline for 7 days as the radical-cure agent
ANSWER: C
Rationale:
With G6PD deficiency excluded, radical cure of vivax is achieved by a standard primaquine course (for example a daily 14-day regimen, or an equivalent approved radical-cure regimen such as single-dose tafenoquine where appropriate), given together with or following the blood schizonticide, to eradicate the dormant liver hypnozoites and prevent further relapse. This is correct.
Option A: Option A is incorrect because a normal G6PD level does not prevent relapse; the hypnozoites must still be eradicated with an 8-aminoquinoline.
Option B: Option B is incorrect because indefinite chloroquine suppression does not eradicate hypnozoites and is not radical cure.
Option D: Option D is incorrect because the single low dose is the falciparum transmission-blocking dose and is inadequate for vivax radical cure, which requires the full antirelapse course.
Option E: Option E is incorrect because doxycycline is a slow blood-stage companion agent with no hypnozoite (radical-cure) activity.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. She is prescribed a 14-day primaquine course and asks why she must keep taking it once she feels completely well, given that her last treatment seemed to work at first. What is the most accurate counseling point?
A) She may stop primaquine as soon as her fever resolves, because symptom resolution indicates the hypnozoites are gone
B) She must complete the full 14-day course even after feeling well, because eradication of the dormant liver hypnozoites requires the entire regimen; stopping early leaves viable hypnozoites and permits another relapse, exactly as occurred when no radical cure was given before
C) Primaquine should be stopped if she feels well to minimize any risk, and relapse can simply be re-treated later
D) The course can be shortened to a few days because primaquine acts only on blood-stage parasites
E) The 14-day course is arbitrary and stopping early has no consequence for relapse
ANSWER: B
Rationale:
Radical cure depends on completing the entire primaquine course; the dormant liver hypnozoites are eradicated only by the full regimen, and symptom resolution reflects clearance of the blood-stage infection, not elimination of the liver reservoir. Stopping early leaves viable hypnozoites and permits another relapse — precisely what happened when she received only blood-stage treatment initially. This is correct.
Option A: Option A is incorrect because symptom resolution reflects blood-stage clearance, not hypnozoite eradication.
Option C: Option C is incorrect because deliberately stopping early and planning to re-treat relapses exposes her to repeated illness and is not appropriate counseling.
Option D: Option D is incorrect because it inverts the pharmacology — primaquine's distinctive action is against the liver hypnozoites, not the blood stage, and the course cannot be shortened on that false premise.
Option E: Option E is incorrect because stopping early directly increases the risk of relapse; the duration is not arbitrary.
9. [CASE 3 — QUESTION 1]
A 31-year-old woman who is 18 weeks pregnant must travel to a rural region with chloroquine-resistant Plasmodium falciparum for 4 weeks. She has no psychiatric history, no seizure history, and no cardiac disease. She asks for the most appropriate malaria chemoprophylaxis. Which agent is preferred?
A) Doxycycline throughout the trip
B) Chloroquine weekly
C) Primaquine daily as causal prophylaxis
D) Mefloquine, started in advance of travel, because it is considered acceptable in pregnancy, is effective against chloroquine-resistant strains, and she has no contraindication to it
E) Tafenoquine as a single pre-travel dose
ANSWER: D
Rationale:
For a pregnant traveler to a chloroquine-resistant area, mefloquine is considered acceptable in pregnancy and is effective against chloroquine-resistant strains; with no psychiatric, seizure, or cardiac contraindication, it is the preferred choice and should be started in advance of travel. This is correct.
Option A: Option A is incorrect because doxycycline is avoided in pregnancy owing to tetracycline effects on fetal bone and teeth.
Option B: Option B is incorrect because chloroquine would be ineffective against a chloroquine-resistant strain.
Option C: Option C is incorrect because primaquine is avoided in pregnancy because fetal G6PD status is unknown and hemolysis cannot be excluded, and it is not used as routine prophylaxis here.
Option E: Option E is incorrect because tafenoquine is an 8-aminoquinoline that requires G6PD testing and is not used in pregnancy for the same fetal-G6PD reason as primaquine.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. She read online that doxycycline is a common prophylaxis for travelers and asks why it was not chosen for her. What is the most accurate explanation?
A) Doxycycline is ineffective against chloroquine-resistant strains, so it would not protect her
B) Doxycycline is avoided in pregnancy because tetracyclines cross the placenta and can affect fetal bone growth and cause discoloration of developing teeth
C) Doxycycline is avoided only because it must be taken daily, which is inconvenient
D) Doxycycline is avoided because it causes oxidative hemolysis in G6PD deficiency
E) Doxycycline is avoided because it characteristically prolongs the QT interval
ANSWER: B
Rationale:
Doxycycline is an effective prophylactic in chloroquine-resistant areas for non-pregnant travelers, but it is avoided in pregnancy because tetracyclines cross the placenta and can affect fetal skeletal (bone) growth and cause discoloration of the developing teeth. That pregnancy-specific safety concern, not efficacy, is why it was not chosen here. This is correct.
Option A: Option A is incorrect because doxycycline is in fact effective in chloroquine-resistant areas; the issue is pregnancy safety, not efficacy.
Option C: Option C is incorrect because the reason is fetal safety, not mere dosing inconvenience.
Option D: Option D is incorrect because oxidative hemolysis in G6PD deficiency is a property of the 8-aminoquinolines, not doxycycline.
Option E: Option E is incorrect because doxycycline is not characteristically QT-prolonging; that concern applies to quinine, quinidine, and certain ACT partner drugs.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. She is prescribed mefloquine and asks when she should begin taking it relative to her departure date. What is the most appropriate instruction and its rationale?
A) Start mefloquine 2 to 3 weeks before departure, so that any neuropsychiatric intolerance can be detected while she is still at home and able to switch to an alternative before reaching a remote area
B) Start mefloquine the day of departure, because it is fully effective immediately and tolerability cannot be predicted
C) Start mefloquine only after arriving at the destination to minimize total exposure
D) Start mefloquine 6 months in advance because it requires prolonged accumulation to become active
E) Timing is irrelevant because mefloquine has no adverse effects worth detecting in advance
ANSWER: A
Rationale:
Mefloquine is started 2 to 3 weeks before departure specifically so that any neuropsychiatric intolerance (vivid dreams, anxiety, mood changes) can surface while the traveler is still at home and able to switch to an alternative agent before reaching a remote destination far from care. This is correct.
Option B: Option B is incorrect because the early start is precisely to assess tolerability in advance, which it claims is impossible.
Option C: Option C is incorrect because starting only after arrival defeats the purpose of detecting intolerance before reaching a remote area and leaves early exposure unprotected.
Option D: Option D is incorrect because mefloquine does not require 6 months of accumulation to act; the lead-in is for tolerability assessment, not activation.
Option E: Option E is incorrect because mefloquine has clinically important neuropsychiatric effects that the advance start is designed to detect.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Three weeks into her trip, while taking mefloquine correctly, she develops a fever. What is the most appropriate counseling regarding fever during chemoprophylaxis?
A) Fever during prophylaxis excludes malaria, so she can safely ignore it
B) She should double her mefloquine dose to treat the presumed breakthrough infection herself
C) Chemoprophylaxis reduces but does not eliminate the risk of malaria, so any fever during or after travel to an endemic area must be evaluated promptly with blood testing, because breakthrough malaria can still occur and requires treatment, not just continued prophylaxis
D) She should stop mefloquine immediately and take no further action
E) Fever is an expected effect of mefloquine and requires no evaluation
ANSWER: C
Rationale:
Chemoprophylaxis substantially reduces but does not completely eliminate the risk of malaria, so breakthrough infection remains possible even with correct adherence. Any fever during or after travel to an endemic area must be promptly evaluated with blood testing (microscopy and/or rapid diagnostic test), because confirmed malaria requires treatment dosing, which differs from prophylaxis. This is correct.
Option A: Option A is incorrect because fever during prophylaxis does not exclude malaria; breakthrough infection can occur.
Option B: Option B is incorrect because self-escalating the prophylactic dose is unsafe and is not appropriate treatment; diagnosis and proper treatment dosing are needed.
Option D: Option D is incorrect because simply stopping the drug without evaluation leaves a potentially serious infection unaddressed.
Option E: Option E is incorrect because fever is not an expected benign effect of mefloquine to be ignored; it warrants evaluation for malaria.
13. [CASE 4 — QUESTION 1]
A 40-year-old man of Mediterranean ancestry is diagnosed with Plasmodium vivax malaria. His acute infection is treated with an appropriate blood schizonticide. Quantitative G6PD testing returns markedly low enzyme activity, consistent with a severe (Mediterranean-type) deficiency. How should this result guide radical-cure planning?
A) Proceed with standard daily primaquine, since the acute infection is already treated
B) Proceed with a single full dose of tafenoquine, which is safe in severe G6PD deficiency
C) Increase the primaquine dose to compensate for reduced red-cell defenses
D) Ignore the G6PD result because hemolysis from 8-aminoquinolines is always mild
E) Recognize that standard-dose 8-aminoquinoline radical cure is unsafe in severe G6PD deficiency because it risks severe, potentially life-threatening hemolysis, and the radical-cure decision must be individualized rather than given at standard dosing
ANSWER: E
Rationale:
A markedly low quantitative G6PD activity (severe, Mediterranean-type deficiency) means standard-dose 8-aminoquinoline radical cure carries a risk of severe, potentially life-threatening oxidative hemolysis. The result must change management: standard-dose primaquine or tafenoquine is unsafe, and the radical-cure approach must be individualized. This is correct.
Option A: Option A is incorrect because proceeding with standard daily primaquine in severe deficiency risks dangerous hemolysis.
Option B: Option B is incorrect because tafenoquine is contraindicated in G6PD deficiency, and its long action makes hemolysis severe and non-reversible.
Option C: Option C is incorrect and dangerous because raising the dose increases oxidative hemolysis, not red-cell protection.
Option D: Option D is incorrect because hemolysis in severe (Mediterranean or Asian) variants can be severe and life-threatening, not uniformly mild.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. A colleague suggests single-dose tafenoquine would be more convenient than a 14-day primaquine course. Why is tafenoquine specifically contraindicated in this patient?
A) Tafenoquine is a blood schizonticide that would not treat hypnozoites anyway
B) Tafenoquine is contraindicated because it characteristically prolongs the QT interval
C) Tafenoquine is contraindicated in G6PD deficiency because its very long half-life produces prolonged, sustained oxidative stress, so any hemolysis it triggers cannot be stopped by discontinuing the drug and may be severe and non-reversible
D) Tafenoquine is contraindicated only in pregnancy, not in G6PD deficiency
E) Tafenoquine is contraindicated because it causes irreversible retinopathy
ANSWER: C
Rationale:
Tafenoquine is a long-acting 8-aminoquinoline; its very long half-life means that if it triggers oxidative hemolysis in a G6PD-deficient patient, the hemolysis cannot be halted by stopping the drug and may be severe and non-reversible. This is the specific reason tafenoquine is contraindicated in G6PD deficiency, whereas a short-acting agent at least allows the offending exposure to be stopped. This is correct.
Option A: Option A is incorrect because tafenoquine is in fact an effective antirelapse (hypnozoite-active) 8-aminoquinoline; the contraindication is about hemolysis, not lack of activity.
Option B: Option B is incorrect because the contraindication here is oxidative hemolysis in G6PD deficiency, not QT prolongation.
Option D: Option D is incorrect because tafenoquine is contraindicated in G6PD deficiency specifically (and also avoided in pregnancy), so limiting the contraindication to pregnancy is wrong.
Option E: Option E is incorrect because retinopathy is a chloroquine/hydroxychloroquine toxicity, not the reason tafenoquine is contraindicated here.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. Given his severe G6PD deficiency, the team still wishes to reduce his risk of vivax relapse. Which individualized radical-cure approach is most appropriate?
A) Standard daily primaquine for 14 days at full dose
B) A supervised intermittent regimen — for example weekly primaquine over 8 weeks — with close hemoglobin monitoring, weighing the relapse-prevention benefit against the hemolysis risk, undertaken with specialist input
C) A single full dose of tafenoquine with planned transfusion support
D) Indefinite daily chloroquine in place of any 8-aminoquinoline
E) No relapse-prevention strategy is possible, so none should ever be attempted
ANSWER: B
Rationale:
In severe G6PD deficiency, when relapse prevention is still desired, a recognized individualized approach is a supervised intermittent regimen such as weekly primaquine given over about 8 weeks, with close hemoglobin monitoring, balancing relapse-prevention benefit against hemolysis risk and undertaken with specialist input. The weekly schedule allows red-cell recovery between doses and reduces the severity of hemolysis compared with daily dosing. This is correct.
Option A: Option A is incorrect because standard daily full-dose primaquine in severe deficiency risks dangerous hemolysis.
Option C: Option C is incorrect because tafenoquine is contraindicated in G6PD deficiency, and planning transfusions around predictable hemolysis from a contraindicated drug is not an accepted strategy.
Option D: Option D is incorrect because indefinite chloroquine does not eradicate hypnozoites and is not radical cure.
Option E: Option E is incorrect because an individualized supervised regimen is possible and is the recognized approach, so categorically abandoning relapse prevention is wrong.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. He begins the supervised weekly primaquine regimen. What monitoring and safety plan is most appropriate during therapy?
A) No monitoring is needed once weekly dosing is chosen, because weekly dosing eliminates hemolysis entirely
B) Monitor only the parasite smear; hemoglobin is irrelevant during radical cure
C) Check renal function weekly but disregard hemoglobin and any urine color change
D) Monitor hemoglobin during therapy and counsel him to report dark urine, fatigue, or jaundice promptly; if clinically significant hemolysis occurs, stop primaquine and provide supportive care, because even weekly dosing can cause hemolysis in severe G6PD deficiency
E) Give a fixed transfusion before each weekly dose regardless of hemoglobin
ANSWER: D
Rationale:
Even with a weekly schedule, primaquine can cause hemolysis in severe G6PD deficiency, so the safety plan is to monitor hemoglobin during therapy and counsel the patient to report dark (cola-colored) urine, fatigue, or jaundice promptly; if clinically significant hemolysis develops, primaquine is stopped and supportive care (including transfusion if severe) is provided. This is correct.
Option A: Option A is incorrect because weekly dosing reduces but does not eliminate hemolysis risk, so monitoring is still required.
Option B: Option B is incorrect because hemoglobin is the key parameter to follow during 8-aminoquinoline therapy in a G6PD-deficient patient, not the smear alone.
Option C: Option C is incorrect because hemoglobin and hemolysis signs (including urine color) are exactly what must be watched; disregarding them is unsafe.
Option E: Option E is incorrect because routine pre-emptive transfusion before each dose is not standard practice; monitoring with treatment of significant hemolysis is appropriate.
17. [CASE 5 — QUESTION 1]
A 35-year-old traveler taking weekly mefloquine for prophylaxis develops vivid nightmares, escalating anxiety, intrusive thoughts, and a sense of detachment from reality after his third weekly dose. He has no prior psychiatric history. What is the most likely explanation for these symptoms?
A) Mefloquine neuropsychiatric toxicity, a recognized adverse effect that can include vivid dreams, anxiety, depersonalization, and, in some patients, frank psychosis or seizures
B) Cinchonism caused by mefloquine, presenting as tinnitus and hearing loss
C) Oxidative hemolysis from mefloquine in an undiagnosed G6PD-deficient patient
D) Mefloquine-induced retinopathy affecting central vision
E) An expected and harmless effect of mefloquine that requires no concern
ANSWER: A
Rationale:
Mefloquine carries a boxed warning for neuropsychiatric toxicity, which can include vivid or disturbing dreams, anxiety, intrusive thoughts, depersonalization, and, in some patients, frank psychosis or seizures. New neuropsychiatric symptoms after starting mefloquine, even without a prior psychiatric history, are most likely due to the drug. This is correct.
Option B: Option B is incorrect because cinchonism (tinnitus, hearing loss) is a toxicity of quinine and quinidine, not the neuropsychiatric syndrome of mefloquine.
Option C: Option C is incorrect because oxidative hemolysis is a property of the 8-aminoquinolines, not mefloquine, and would not present as neuropsychiatric symptoms.
Option D: Option D is incorrect because retinopathy is a chloroquine/hydroxychloroquine toxicity and would not cause these psychiatric features.
Option E: Option E is incorrect because these are clinically significant neuropsychiatric symptoms that warrant action, not a harmless expected effect.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. He is still in a malaria-endemic area and needs ongoing protection. What is the most appropriate immediate management of his mefloquine-related symptoms?
A) Continue mefloquine and add a sedative, since the symptoms will habituate
B) Increase the mefloquine dose to push through the adverse effects
C) Continue mefloquine unchanged but reassure him the symptoms are imaginary
D) Discontinue mefloquine immediately and switch to an alternative prophylactic agent (for example atovaquone-proguanil or doxycycline) to maintain protection without continuing the offending drug
E) Stop all prophylaxis entirely and provide no replacement
ANSWER: D
Rationale:
Mefloquine neuropsychiatric symptoms warrant immediate discontinuation, and because the patient remains in an endemic area he needs continued protection; the correct action is to stop mefloquine and switch to an alternative prophylactic such as atovaquone-proguanil or doxycycline. This is correct.
Option A: Option A is incorrect because continuing the offending drug and masking symptoms risks progression to severe neuropsychiatric events; these symptoms should not be expected to simply habituate.
Option B: Option B is incorrect and dangerous because a higher dose intensifies neuropsychiatric toxicity.
Option C: Option C is incorrect because the symptoms are real adverse drug effects, not imaginary, and the drug should be stopped.
Option E: Option E is incorrect because stopping prophylaxis with no replacement leaves him unprotected in an endemic area; an alternative agent is needed.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. In reviewing how mefloquine was selected, the team revisits its contraindications. Which set of conditions represents recognized contraindications or cautions to mefloquine that should be screened for before prescribing it?
A) A history of penicillin allergy and lactose intolerance
B) A history of well-controlled hypertension and seasonal allergies alone
C) A history of psychiatric disorders (such as depression, anxiety, or psychosis), a seizure disorder, and cardiac conduction abnormalities — conditions in which mefloquine is contraindicated or used only with caution
D) A history of prior uncomplicated malaria, which permanently contraindicates mefloquine
E) Any history of travel, which contraindicates mefloquine
ANSWER: C
Rationale:
Mefloquine is contraindicated or used only with caution in patients with a history of psychiatric disorders (including depression, anxiety, and psychosis), a seizure disorder, and certain cardiac conduction abnormalities; these are the conditions that should be screened for before prescribing. This is correct.
Option A: Option A is incorrect because penicillin allergy and lactose intolerance are not mefloquine contraindications.
Option B: Option B is incorrect because well-controlled hypertension and seasonal allergies alone are not contraindications to mefloquine.
Option D: Option D is incorrect because a history of prior uncomplicated malaria does not permanently contraindicate mefloquine.
Option E: Option E is incorrect because a history of travel is not a contraindication; the relevant screen is for psychiatric, seizure, and cardiac conduction conditions.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. He is traveling in a chloroquine-resistant region and has another 2 weeks of exposure. Mefloquine is now excluded. He is not pregnant and has no contraindication to tetracyclines or to atovaquone-proguanil. Which replacement prophylaxis is most appropriate, and why?
A) Chloroquine, because switching drug classes restores susceptibility
B) Atovaquone-proguanil or doxycycline, because both are effective in chloroquine-resistant areas and neither carries mefloquine's neuropsychiatric liability
C) A second course of mefloquine at a lower dose, because the problem was the dose, not the drug
D) Primaquine monotherapy as routine prophylaxis without G6PD testing
E) No replacement, because two weeks of unprotected exposure is acceptable
ANSWER: B
Rationale:
With mefloquine excluded, effective prophylaxis in a chloroquine-resistant area is provided by atovaquone-proguanil or doxycycline; both are appropriate for this patient (no pregnancy, no tetracycline contraindication) and neither carries the neuropsychiatric liability of mefloquine. This is correct.
Option A: Option A is incorrect because chloroquine would be ineffective against the chloroquine-resistant strain.
Option C: Option C is incorrect because the adverse effect was neuropsychiatric toxicity of the drug, not simply a dosing issue, so re-challenging with mefloquine is inappropriate.
Option D: Option D is incorrect because primaquine is not used as routine sole prophylaxis here and must never be given without G6PD testing.
Option E: Option E is incorrect because leaving him unprotected for two more weeks in an endemic area is unsafe when effective alternatives exist.
21. [CASE 6 — QUESTION 1]
A 38-year-old aid worker returns from the Thailand-Cambodia border region with uncomplicated falciparum malaria and begins an artemisinin-based combination therapy. Despite confirmed adherence and correct dosing, daily smears show that parasitemia falls much more slowly than expected, with parasites still present on day 3. What does this slow response most likely represent?
A) Delayed parasite clearance, the clinical signature of artemisinin partial resistance, which is well documented in the Greater Mekong region and reflects reduced susceptibility to the artemisinin component
B) Normal, expected clearance kinetics that require no concern
C) Reinfection by a new mosquito bite during treatment
D) Laboratory contamination of the blood smears
E) An allergic reaction to the artemisinin component
ANSWER: A
Rationale:
Delayed parasite clearance — a prolonged parasite clearance time with parasites still detectable on day 3 despite correct ACT therapy — is the clinical signature of artemisinin partial resistance, which is well documented in the Greater Mekong region (including the Thailand-Cambodia border). It reflects reduced susceptibility to the artemisinin component associated with pfkelch13 mutations. This is correct.
Option B: Option B is incorrect because an adequate ACT response normally produces rapid, marked parasite reduction by day 3; persistent slow clearance is abnormal.
Option C: Option C is incorrect because reinfection during treatment would not explain failure of the existing parasitemia to clear, and the pattern fits resistance.
Option D: Option D is incorrect because consistent slow clearance across serial smears is a recognized biological phenomenon, not contamination.
Option E: Option E is incorrect because slow parasite clearance is a resistance pattern, not an allergic reaction.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. The team understands that artemisinin partial resistance alone often does not cause outright treatment failure. What additional factor most importantly converts delayed clearance into actual clinical treatment failure?
A) Spontaneous resolution of the infection without any drug effect
B) Improved host immunity during treatment
C) Concurrent resistance to the longer-acting partner drug (for example piperaquine resistance, mediated by plasmepsin 2-3 gene amplification), which removes the backup that normally clears residual parasites after the short-lived artemisinin is gone
D) A shorter artemisinin half-life caused by the resistance
E) Increased dietary fat intake during therapy
ANSWER: C
Rationale:
Artemisinin partial resistance alone often does not cause clinical failure because the longer-acting partner drug still clears residual parasites. Clinical treatment failure emerges when resistance to the partner drug also develops — for example piperaquine resistance mediated by plasmepsin 2-3 gene amplification — which removes the backup that normally finishes parasite clearance after the short-lived artemisinin is gone. This is correct.
Option A: Option A is incorrect because falciparum infection does not reliably resolve spontaneously, and treatment failure here reflects drug resistance, not spontaneous cure.
Option B: Option B is incorrect because improved immunity would reduce, not cause, treatment failure.
Option D: Option D is incorrect because the artemisinin half-life is a fixed pharmacokinetic property and does not shorten because of resistance; the issue is partner-drug failure.
Option E: Option E is incorrect because dietary fat affects lumefantrine absorption specifically but is not the factor converting delayed clearance into treatment failure in this resistance scenario.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. By day 3 he still has significant parasitemia and the response is judged a treatment failure. What is the most appropriate management step?
A) Continue the same ACT for several more days without any change
B) Add chloroquine to the failing ACT to restore artemisinin activity
C) Switch to oral primaquine monotherapy to clear the blood-stage parasites
D) Stop treatment and observe, allowing the parasites to clear on their own
E) Treat as a treatment failure by switching to an effective alternative regimen — for example parenteral artesunate together with a different, region-effective partner drug (or an alternative ACT whose partner drug remains effective) — and arrange close follow-up
ANSWER: E
Rationale:
A confirmed ACT treatment failure should be managed by switching to an effective alternative regimen rather than persisting with the failing therapy. Appropriate options include parenteral artesunate combined with a different, region-effective partner drug, or an alternative ACT whose partner drug remains effective in that region, with close follow-up of parasite clearance. This is correct.
Option A: Option A is incorrect because continuing the same failing ACT unchanged will not overcome the resistance.
Option B: Option B is incorrect because chloroquine does not restore artemisinin activity and has no role here.
Option C: Option C is incorrect because primaquine does not treat acute blood-stage falciparum infection.
Option D: Option D is incorrect because falciparum malaria is potentially fatal and persistent parasitemia must not be left untreated.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. Beyond treating this individual, the team wants to document and track the suspected resistance. Which approach is most appropriate for confirming and monitoring artemisinin resistance in this setting?
A) Rely solely on the patient's symptom diary to define resistance
B) Assume resistance is impossible and take no further measurements
C) Use serologic antibody titers as the definitive marker of artemisinin resistance
D) Quantify parasite clearance (for example clearance half-life from serial smears) and perform molecular genotyping for pfkelch13 propeller-domain mutations, while using genotyping to distinguish recrudescence from reinfection, contributing to resistance surveillance
E) Measure the patient's drug allergy panel to confirm resistance
ANSWER: D
Rationale:
Confirming and monitoring artemisinin partial resistance relies on quantifying parasite clearance (for example the parasite clearance half-life from serial smears) and molecular genotyping for pfkelch13 propeller-domain mutations, the validated marker of artemisinin partial resistance; genotyping also distinguishes recrudescence (same parasite, true failure) from reinfection (new parasite), contributing to surveillance. This is correct.
Option A: Option A is incorrect because a symptom diary cannot define or confirm drug resistance.
Option B: Option B is incorrect because resistance is well documented in this region and must be measured, not dismissed.
Option C: Option C is incorrect because serology reflects past exposure and is not a marker of artemisinin resistance.
Option E: Option E is incorrect because a drug allergy panel has nothing to do with confirming antimalarial resistance.
25. [CASE 7 — QUESTION 1]
A 58-year-old man with coronary artery disease is treated with oral quinine plus doxycycline for uncomplicated malaria in a setting where an ACT is temporarily unavailable. On the second day he reports ringing in the ears, mild reversible high-frequency hearing changes, headache, and nausea. His blood glucose is normal and his mental status is intact. What does this symptom cluster most likely represent?
A) Hypoglycemia from quinine-induced insulin secretion
B) Cinchonism, the characteristic quinine and quinidine toxicity syndrome of tinnitus, high-frequency hearing changes, headache, and nausea, which occurs at therapeutic or mildly elevated levels and is usually not dose-limiting in short treatment courses
C) Acute oxidative hemolysis from quinine in G6PD deficiency
D) Mefloquine-type neuropsychiatric toxicity
E) Quinine-induced retinopathy
ANSWER: B
Rationale:
The cluster of tinnitus, high-frequency hearing changes, headache, and nausea is cinchonism, the characteristic toxicity syndrome of quinine and quinidine. It occurs at therapeutic or mildly supratherapeutic concentrations and is usually not dose-limiting during the short courses used to treat malaria, resolving when the drug is stopped. This is correct.
Option A: Option A is incorrect because his glucose is normal and the described symptoms are the sensory cluster of cinchonism, not the diaphoresis and confusion of hypoglycemia.
Option C: Option C is incorrect because oxidative hemolysis would present with dark urine and a falling hemoglobin, not tinnitus and hearing changes, and is a feature of the 8-aminoquinolines.
Option D: Option D is incorrect because these are not the neuropsychiatric features of mefloquine, and he is taking quinine.
Option E: Option E is incorrect because retinopathy is a chloroquine/hydroxychloroquine toxicity and does not present as this acute auditory and gastrointestinal cluster.
26. [CASE 7 — QUESTION 2]
Continuing with the same patient. Later that day he becomes acutely diaphoretic, tremulous, and confused, which is a clear change from his earlier sensory complaints. What is the most important immediate step?
A) Attribute the new symptoms to worsening cinchonism and simply continue quinine unchanged
B) Give intravenous potassium for presumed hyperkalemia
C) Obtain an urgent head CT before any bedside intervention
D) Administer intravenous antihypertensives for presumed hypertensive crisis
E) Check the blood glucose immediately and treat hypoglycemia, because quinine stimulates pancreatic insulin secretion and can cause hypoglycemia, which is a distinct, reversible cause of new diaphoresis, tremor, and confusion separate from cinchonism
ANSWER: E
Rationale:
A new picture of diaphoresis, tremor, and confusion — distinct from the earlier sensory cinchonism — should prompt an immediate bedside glucose check, because quinine stimulates pancreatic insulin secretion and can cause hypoglycemia, a reversible and dangerous complication that must be treated promptly. This is correct.
Option A: Option A is incorrect because these features indicate a new problem (hypoglycemia), not merely worsening cinchonism, and continuing quinine without checking glucose is unsafe.
Option B: Option B is incorrect because quinine toxicity is associated with hypoglycemia, not hyperkalemia, and empiric potassium could be harmful.
Option C: Option C is incorrect because, although neurologic causes are considered, the immediate, reversible, and most likely cause to check first is hypoglycemia.
Option D: Option D is incorrect because the picture is hypoglycemia, not a hypertensive crisis.
27. [CASE 7 — QUESTION 3]
Continuing with the same patient. Given his coronary artery disease, the team is attentive to quinine's cardiac effects. Which statement best describes the appropriate cardiac precaution during quinine therapy?
A) Quinine has no effect on cardiac conduction, so no monitoring is needed
B) Quinine shortens the QT interval, so it protects against arrhythmia in cardiac patients
C) Quinine should be combined freely with other QT-prolonging drugs without concern
D) Quinine can prolong the QT interval and affect cardiac conduction, so ECG monitoring is appropriate, electrolytes (potassium and magnesium) should be corrected, and concurrent use of other QT-prolonging agents should be avoided, particularly in a patient with underlying cardiac disease
E) Quinine toxicity is limited entirely to the ears and has no cardiac relevance
ANSWER: D
Rationale:
Quinine (and especially its stereoisomer quinidine) can prolong the QT interval and affect cardiac conduction. In a patient with underlying cardiac disease, appropriate precautions include ECG monitoring, correction of potassium and magnesium, and avoiding concurrent QT-prolonging agents. This is correct.
Option A: Option A is incorrect because quinine does affect cardiac conduction and can prolong the QT interval.
Option B: Option B is incorrect because quinine prolongs, rather than shortens, the QT interval and does not protect against arrhythmia.
Option C: Option C is incorrect because combining quinine with other QT-prolonging drugs increases arrhythmia risk and should be avoided.
Option E: Option E is incorrect because quinine toxicity is not limited to the ears; its cardiac effects are clinically relevant, particularly in cardiac patients.
28. [CASE 7 — QUESTION 4]
Continuing with the same patient. He asks why he is taking doxycycline along with the quinine. What is the most accurate explanation of the regimen design?
A) Quinine is paired with a companion antibiotic such as doxycycline (or clindamycin) for a 7-day course because quinine has a narrow therapeutic index and incomplete efficacy alone, and the companion agent improves cure rates and reduces selection of resistance
B) The doxycycline is included only to treat an unrelated bacterial infection and has no antimalarial role
C) Doxycycline is a rapidly acting antimalarial that cures malaria within hours, making the quinine unnecessary
D) Doxycycline is added to eradicate liver hypnozoites and prevent relapse of falciparum
E) Doxycycline is added solely to mask the symptoms of cinchonism
ANSWER: A
Rationale:
Quinine has a narrow therapeutic index and limited efficacy when used alone, so it is paired with a companion antibiotic such as doxycycline (or clindamycin) over a 7-day course to improve cure rates and reduce the selection of resistance. This is correct.
Option B: Option B is incorrect because the companion antibiotic is an integral part of the antimalarial regimen, not treatment for a separate bacterial infection.
Option C: Option C is incorrect because doxycycline is a slow-acting antimalarial and cannot rapidly cure malaria alone; quinine provides the rapid blood-stage activity.
Option D: Option D is incorrect because doxycycline does not eradicate hypnozoites, and falciparum forms no hypnozoites requiring radical cure.
Option E: Option E is incorrect because the companion antibiotic has a genuine antiparasitic purpose and is not given to mask cinchonism.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.